Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 31;69(1):e0064623.
doi: 10.1128/aac.00646-23. Epub 2024 Dec 12.

New Perspectives on Antimicrobial Agents: Rezafungin

Nicholas M Forrister  1 , Todd P McCarty  1   2 , Peter G Pappas  1
Affiliations
Review

New Perspectives on Antimicrobial Agents: Rezafungin

Nicholas M Forrister et al. Antimicrob Agents Chemother. .

Abstract

Candidemia and invasive candidiasis persist as significant causes of morbidity and mortality. As fluconazole resistance rates rise, alternative means of treatment are necessary, either via mold-active azoles or extended durations of echinocandins. These come with the potential for undesirable side effects for triazoles or choosing between prolonged hospitalization or outpatient parenteral antimicrobial therapy in the case of echinocandins. Rezafungin offers an opportunity to manage extended treatment durations with shorter hospital stays and no extended parenteral access. Herein, we review the most recent published data pertaining to rezafungin including anti-fungal activity, pharmacokinetics, and clinical data relating to the treatment of invasive candidiasis. Given its prolonged half-life allowing for once-weekly dosing, rezafungin has the potential as an anti-fungal prophylactic agent in high-risk patients, and studies to examine this potential role are ongoing.

Keywords: anti-fungal agents; candidemia; echinocandin; invasive candidiasis.

PubMed Disclaimer

Conflict of interest statement

N.M.F. has nothing to disclose. T.P.M. has the following disclosures: consulting for Pfizer; research contracts for F2G, Cidara, Basilea, Mundipharma, and Scynexis. P.G.P. has the following disclosures: research support from F2G, Melinta, Scynexis, Astellas, and Gilead; scientific advisory board of F2G, Melinta, Basilea, ISHA Pharma, and GSK.

References

    1. Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, Sobel JD, Herbrecht R, Rahav G, Jaruratanasirikul S, Chetchotisakd P, Van Wijngaerden E, De Waele J, Lademacher C, Engelhardt M, Kovanda L, Croos-Dabrera R, Fredericks C, Thompson GR. 2019. Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: the ACTIVE trial. Clin Infect Dis 68:1981–1989. doi: 10.1093/cid/ciy827 - DOI - PubMed
    1. McCarty TP, White CM, Pappas PG. 2021. Candidaemia and invasive candidasis. Infect Dis Clin North Am 35:389–413. doi: 10.1016/j.idc.2021.03.007 - DOI - PubMed
    1. Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J. 2008. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 52:3497–3503. doi: 10.1128/AAC.00478-08 - DOI - PMC - PubMed
    1. Bader JC, Bhavnani SM, Andes DR, Ambrose PG. 2018. We can do better: a fresh look at echinocandin dosing. J Antimicrob Chemother 73:i44–i50. doi: 10.1093/jac/dkx448 - DOI - PubMed
    1. Garcia-Effron G. 2020. Rezafungin—mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins. J Fungi (Basel) 6:262. doi: 10.3390/jof6040262 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources